Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

By Naoyuki Nakao, A. Yoshimura, Hiroyuki Morita, Masyuki Takada, Tsuguo Kayano, Terukuni Ideura. The Lancet, 2003

846 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/5996853ed8dd0da81cdadd3e202eb6dd2df14477

Citations in the corpus

• 2007 ESH‐ESC Guidelines for the management of arterial hypertension (2007, neutral): “(446) Other studies have shown a greater antiproteinuric action of the combination, associated, however, with a greater blood pressure reduction; (447,448) indeed, when the ACE inhibitor dose was titrated to obtain the same blood pressure decrease as the combination, no difference in the antiprotein”